Medgenics, Inc. (MDGN)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
5.63+0.03 (+0.54%)
At close: 4:02 PM EDT
People also watch:
CFRXMNOVFCSCMRTXSYN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open5.63
Prev Close5.60
Bid5.63 x 1000
Ask5.66 x 900
Day's Range5.51 - 5.71
52wk Range3.09 - 8.33
1y Target EstN/A
Market Cap208.75M
P/E Ratio (ttm)-3.80
Beta0.23
Volume103,738
Avg Vol (3m)99,521
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Marketwired22 days ago

    Medgenics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

    Medgenics, Inc. today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Monday, September ...

  • MDGN: Several Upcoming Milestones Including NFC-1 ADHD Phase 2/3 Data
    Zacks Small Cap Research2 months ago

    MDGN: Several Upcoming Milestones Including NFC-1 ADHD Phase 2/3 Data

    Medgenics (MDGN) reported financial results for the second quarter ending June 30th and provided and operational update including status reports on their NFC-1 programs in ADHD and 22q Deletion Syndrome as well as their anti-LIGHT candidate targeting severe pediatric onset IBD. Q2 net loss and EPS were $11.7M and ($0.35), compared to our $11.4M and ($0.35) estimates.  Cash used in operating activities was $9.8M and $18.9M in the first three and six months of 2016.  Cash balance, bolstered by the June equity raise (3.8M shares @ $5.50/share) which netted ~$19.7M, was $53.7M at quarter end.  The sizeable raise and beefed-up cash balance allows development programs to remain on track and at their accelerated pace.  Management expects current cash to fund operations through Q1 2018.  By that time NFC-1 should have significant data points in both mGlurR+ ADHD and 22q and initial responder data should be available from the anti-LIGHT program.

  • Associated Press2 months ago

    Medgenics reports 2Q loss

    On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 35 cents. Medgenics shares have fallen slightly since the beginning of the year. The stock has dropped 23 percent in the ...